Related Experiment Video
Updated: Jul 17, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Antiproliferative activity of Titanocene Y against tumor colony-forming units
Olaf Oberschmidt1, Axel R Hanauske, Clara Pampillón
1Asklepios Klinik St Georg Hamburg, Hamburg, Germany.
Abstract:
Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized titanium-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 micromol/l against a range of freshly explanted human tumors, using an in-vitro soft agar cloning system. The sensitivity against Titanocene Y was highly remarkable in the case of renal cell, ovarian, nonsmall cell lung and colon cancer. In particular the surprisingly good response of nonsmall cell lung cancer and colon cancer against Titanocene Y at its lowest concentration of 2.1 micromol/l was well comparable or better with respect to cisplatin, given at a concentration of 1.0 micromol/l. Further clinical development of Titanocene Y appears to be warranted because of the broad cytotoxic activity shown and the specific activity of Titanocene Y against renal cell cancer.
Insights
Titanocene Y, a novel titanium anticancer drug, shows remarkable antitumor activity against renal cell, ovarian, lung, and colon cancers. Its effectiveness, particularly in lung and colon cancers at low doses, warrants further clinical investigation.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Titanocene Y (Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride) is a new titanium-based compound with potential anticancer properties.
- Titanium compounds are being explored for their therapeutic applications in cancer treatment.
Purpose of the Study:
- To evaluate the in-vitro antitumor activity of Titanocene Y against a panel of human tumors.
- To compare the efficacy of Titanocene Y with cisplatin in sensitive cancer types.
Main Methods:
- Utilized a soft agar cloning system for in-vitro drug sensitivity testing.
- Tested Titanocene Y at concentrations of 2.1, 21, and 210 micromol/l.
- Assessed responses in freshly explanted human tumor samples.
Main Results:
- Titanocene Y demonstrated significant sensitivity in renal cell, ovarian, nonsmall cell lung, and colon cancers.
- Nonsmall cell lung and colon cancers showed notable responses to Titanocene Y at 2.1 micromol/l, comparable or superior to cisplatin at 1.0 micromol/l.
- Broad cytotoxic activity was observed across various tumor types.
Conclusions:
- Titanocene Y exhibits promising broad-spectrum cytotoxic activity against human tumors.
- The drug shows specific efficacy against renal cell cancer.
- Further clinical development of Titanocene Y is strongly recommended based on these in-vitro findings.
